David Schanzlin, MD
Ophthalmology · San Diego, CANPI 1528016417
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Oasis Medical, Inc. at 48.4% of the total. Reporting peaked in 2019 at $9,554 and has fallen 77.9% since, to $2,110 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $97.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Oasis Medical, Inc.$9K
- Glaukos Corporation$3K
- Alcon$3K
- Biotissue Holdings Inc.$759
- Harrow Eye, LLC$646
- Bausch & Lomb Americas Inc.$507
- plus $2K from 17 others
Across 45 payments — averaging $12,606 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sight Sciences, Inc.$217K
- Oyster Point Pharma, Inc.$215K
- Novartis$96K
- Dompe US, Inc.$36K
- Dompe Farmaceutici S.p.a.$3K
- Topcon Healthcare, Inc.$333
What the payments were for
- Consulting fees$10,83858%
- Speaking & faculty fees$7004%
- Travel & lodging$150%
- Food & beverage$7,02838%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Oasis Medical, Inc. | 3 | $9,000 |
| Glaukos Corporation | 16 | $3,049 |
| Alcon | 86 | $2,791 |
| Biotissue Holdings Inc. | 8 | $759 |
| Harrow Eye, LLC | 13 | $646 |
| Bausch & Lomb Americas Inc. | 18 | $507 |
| Carl Zeiss Meditec USA, Inc. | 2 | $282 |
| Rxsight Inc | 5 | $278 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $208 |
| Sight Sciences, Inc. | 1 | $148 |
| Sun Pharmaceutical Industries Inc. | 5 | $116 |
| Carl Zeiss Meditec, Inc. | 1 | $114 |
| Tarsus Pharmaceuticals, Inc. | 4 | $113 |
| Ocular Therapeutix, Inc. | 6 | $103 |
| Dompe US, Inc. | 3 | $88 |
| Novartis | 4 | $78 |
| Oyster Point Pharma, Inc. | 3 | $70 |
| AbbVie(2 entities) | 3 | $68 |
| Ivantis, Inc | 1 | $54 |
| Shire North American Group Inc | 2 | $42 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $24 |
| Thea Pharma Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KXL System$634
- iStent Infinite$400
- iDoseTR$400
- ARTEVO 800$396
- CE-marked KXLA system$300
- enVista MX60 IOL$262
- Clareon$150
- OMNI(R) SURGICAL SYSTEM (US)$148
- SION SURGICAL INSTRUMENT$148
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$147
- AcrySof$131
- Photrexa Viscous and Photrexa$125
- ARGOS$124
- Clareon PanOptix Pro$121
- Unity$117
- CALLISTO eye$114
- VERACITY SURGICAL$114
- Photrexa$108
How this compares
$18,581 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Loteprednol Etabonate | 12 | $1,667 |
| Prednisolone Acetate | 19 | $841 |
| MoxifloxacinMoxifloxacin Hcl | 14 | $209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $208 | $1,66712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in San Diego
- Robert WeinrebSan Diego$520K
- Eric NudlemanSan Diego$343K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.